Univariable and multivariable Cox modeling on PFS analysis among patients who received systemic therapy
| Variable . | Univariate . | Multivariable . | ||
|---|---|---|---|---|
| HR (95% CI) . | P value . | HR (95% CI) . | P value . | |
| Monoclonal protein | ||||
| No M-protein | 1.00 | 1.00 | ||
| M-protein | 1.60 (1.19-2.16) | .002 | 1.74 (1.20-2.54) | .004 |
| Age (y) | 1.02 (1.00-1.03) | .01 | 1.01 (0.99-1.02) | .46 |
| Sex | ||||
| Males | 1.00 | .71 | - | - |
| Females | 0.94 (0.67-1.32) | - | - | |
| ECOG PS | ||||
| 0 | 1.00 | 1.00 | ||
| 1 | 1.50 (1.05-2.16) | .03 | 1.34 (0.91-1.97) | .14 |
| ≥2 | 1.62 (0.89-2.94) | .12 | 1.31 (0.69-2.51) | .41 |
| B symptoms | ||||
| No | 1.00 | - | - | |
| Yes | 1.23 (0.87-1.73) | .23 | - | - |
| MZL subtype | ||||
| NMZL | 1.00 | 1.00 | ||
| SMZL | 0.87 (0.58-1.29) | .48 | 0.66 (0.40-1.09) | .10 |
| EMZL | 0.68 (0.48-0.97) | .03 | 0.61 (0.39-0.97) | .03 |
| Stage | ||||
| 1-2 | 1.00 | - | - | |
| 3-4 | 1.14 (0.76-1.71) | .51 | - | - |
| LDH > ULN | ||||
| No | 1.00 | 1.00 | ||
| Yes | 1.70 (1.24-2.35) | .001 | 1.55 (1.05-2.30) | .03 |
| Albumin < ULN | ||||
| Normal | 1.00 | 1.00 | ||
| Low | 1.35 (0.93-1.97) | .11 | 1.10 (0.72-1.69) | .66 |
| BM involvement | ||||
| No | 1.00 | - | - | |
| Yes | 1.09 (0.77-1.53) | .64 | - | - |
| First-line treatment | ||||
| R alone | 1.00 | 1.00 | ||
| R-chemotherapy | 0.65 (0.47-0.89) | .007 | 0.64 (0.43-0.95) | .03 |
| Others | 0.57 (0.18-1.80) | .34 | 0.47 (0.14-1.52) | .21 |
| Variable . | Univariate . | Multivariable . | ||
|---|---|---|---|---|
| HR (95% CI) . | P value . | HR (95% CI) . | P value . | |
| Monoclonal protein | ||||
| No M-protein | 1.00 | 1.00 | ||
| M-protein | 1.60 (1.19-2.16) | .002 | 1.74 (1.20-2.54) | .004 |
| Age (y) | 1.02 (1.00-1.03) | .01 | 1.01 (0.99-1.02) | .46 |
| Sex | ||||
| Males | 1.00 | .71 | - | - |
| Females | 0.94 (0.67-1.32) | - | - | |
| ECOG PS | ||||
| 0 | 1.00 | 1.00 | ||
| 1 | 1.50 (1.05-2.16) | .03 | 1.34 (0.91-1.97) | .14 |
| ≥2 | 1.62 (0.89-2.94) | .12 | 1.31 (0.69-2.51) | .41 |
| B symptoms | ||||
| No | 1.00 | - | - | |
| Yes | 1.23 (0.87-1.73) | .23 | - | - |
| MZL subtype | ||||
| NMZL | 1.00 | 1.00 | ||
| SMZL | 0.87 (0.58-1.29) | .48 | 0.66 (0.40-1.09) | .10 |
| EMZL | 0.68 (0.48-0.97) | .03 | 0.61 (0.39-0.97) | .03 |
| Stage | ||||
| 1-2 | 1.00 | - | - | |
| 3-4 | 1.14 (0.76-1.71) | .51 | - | - |
| LDH > ULN | ||||
| No | 1.00 | 1.00 | ||
| Yes | 1.70 (1.24-2.35) | .001 | 1.55 (1.05-2.30) | .03 |
| Albumin < ULN | ||||
| Normal | 1.00 | 1.00 | ||
| Low | 1.35 (0.93-1.97) | .11 | 1.10 (0.72-1.69) | .66 |
| BM involvement | ||||
| No | 1.00 | - | - | |
| Yes | 1.09 (0.77-1.53) | .64 | - | - |
| First-line treatment | ||||
| R alone | 1.00 | 1.00 | ||
| R-chemotherapy | 0.65 (0.47-0.89) | .007 | 0.64 (0.43-0.95) | .03 |
| Others | 0.57 (0.18-1.80) | .34 | 0.47 (0.14-1.52) | .21 |
BM, bone marrow; ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; ULN, upper limit of normal.